Price T Rowe Associates Inc. MD Has $27.11 Million Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON)

Price T Rowe Associates Inc. MD grew its stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 59.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 945,194 shares of the company's stock after acquiring an additional 353,787 shares during the quarter. Price T Rowe Associates Inc. MD owned 1.24% of CG Oncology worth $27,109,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. NEOS Investment Management LLC raised its holdings in CG Oncology by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 8,329 shares of the company's stock worth $239,000 after purchasing an additional 817 shares during the period. Rhumbline Advisers lifted its holdings in CG Oncology by 2.2% during the fourth quarter. Rhumbline Advisers now owns 69,016 shares of the company's stock worth $1,979,000 after acquiring an additional 1,458 shares in the last quarter. MetLife Investment Management LLC grew its stake in CG Oncology by 7.0% in the fourth quarter. MetLife Investment Management LLC now owns 29,026 shares of the company's stock valued at $832,000 after acquiring an additional 1,894 shares during the period. New York State Common Retirement Fund grew its stake in CG Oncology by 16.7% in the fourth quarter. New York State Common Retirement Fund now owns 13,996 shares of the company's stock valued at $401,000 after acquiring an additional 2,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of CG Oncology in the fourth quarter worth about $68,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

CG Oncology Stock Performance

CG Oncology stock traded down $0.50 during midday trading on Monday, reaching $28.55. 458,557 shares of the company's stock were exchanged, compared to its average volume of 780,995. The stock's 50-day simple moving average is $23.68 and its 200 day simple moving average is $28.90. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -20.15 and a beta of 1.08. CG Oncology, Inc. has a 52 week low of $14.80 and a 52 week high of $40.47.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.11 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. Research analysts forecast that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Insider Transactions at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the company's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $30.76, for a total value of $30,760.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CGON shares. JPMorgan Chase & Co. assumed coverage on CG Oncology in a research note on Friday. They set an "overweight" rating and a $41.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 target price on shares of CG Oncology in a research note on Monday, April 28th. TD Cowen assumed coverage on CG Oncology in a research note on Tuesday, January 7th. They issued a "buy" rating on the stock. Morgan Stanley reaffirmed an "overweight" rating and set a $55.00 price target on shares of CG Oncology in a research note on Friday, March 7th. Finally, Scotiabank began coverage on shares of CG Oncology in a research report on Wednesday, April 16th. They issued a "sector perform" rating and a $23.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $57.70.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.